國立虎尾科技大學 |

Regulation of Genome Editing in Human iPS Cells = A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Regulation of Genome Editing in Human iPS Cells/ edited by Hans-Georg Dederer, Gregor Frenken.
Reminder of title:	A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies /
other author:	Dederer, Hans-Georg.
Description:	X, 334 p. 13 illus., 10 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Private international law. -
Online resource:	https://doi.org/10.1007/978-3-030-93023-3
ISBN:	9783030930233

Regulation of Genome Editing in Human iPS Cells = A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies /
Regulation of Genome Editing in Human iPS CellsA Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies /[electronic resource] :edited by Hans-Georg Dederer, Gregor Frenken. - 1st ed. 2022. - X, 334 p. 13 illus., 10 illus. in color.online resource.

Introduction -- Biological Aspects of Genome Editing in iPS Cells -- Ethical Aspects in the Context of Genome Editing -- Regulation of Genome Editing in iPS Cells: Germany -- Regulation of Genome Editing in iPS Cells: France -- Regulation of Genome Editing in iPS Cells: Switzerland -- Regulation of Genome Editing in iPS Cells: United States -- Regulation of Genome Editing in iPS Cells: Japan -- Regulation of Genome Editing in iPS Cells: Republic of Korea -- Comparative Analysis.

The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells). Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers.

ISBN: 9783030930233

Standard No.: 10.1007/978-3-030-93023-3doiSubjects--Topical Terms:

1202562
Private international law.

LC Class. No.: K7000-7720.22

Dewey Class. No.: 340.9

Regulation of Genome Editing in Human iPS Cells = A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies /
LDR:03717nam a22004215i 4500 001 1086490
003 DE-He213
005 20220523120210.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030930233 $9 978-3-030-93023-3
024 7 $a 10.1007/978-3-030-93023-3 $2 doi
035 $a 978-3-030-93023-3
050 4 $a K7000-7720.22
072 7 $a LB $2 bicssc
072 7 $a LAM $2 bicssc
072 7 $a LAW051000 $2 bisacsh
072 7 $a LB $2 thema
072 7 $a LAM $2 thema
082 0 4 $a 340.9 $2 23
245 1 0 $a Regulation of Genome Editing in Human iPS Cells $h [electronic resource] : $b A Comparative Legal Analysis of National Regulatory Frameworks for iPSC-based Cell/Gene Therapies / $c edited by Hans-Georg Dederer, Gregor Frenken.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a X, 334 p. 13 illus., 10 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Introduction -- Biological Aspects of Genome Editing in iPS Cells -- Ethical Aspects in the Context of Genome Editing -- Regulation of Genome Editing in iPS Cells: Germany -- Regulation of Genome Editing in iPS Cells: France -- Regulation of Genome Editing in iPS Cells: Switzerland -- Regulation of Genome Editing in iPS Cells: United States -- Regulation of Genome Editing in iPS Cells: Japan -- Regulation of Genome Editing in iPS Cells: Republic of Korea -- Comparative Analysis.
520 $a The book provides a concise overview of currently applicable regulatory frameworks of states which are among the world leaders in research and development (R&D) of cell and gene therapies. Developments in genome editing are expected to lead to new possibilities for the treatment of hereditary diseases in humans. The treatment of such often severe but hitherto uncurable diseases can be based on genome-edited induced pluripotent stem cells (iPS cells). Such treatments constitute combined cell/gene therapies. These therapies need to be governed by a regulatory framework which ensures quality, safety, and efficacy of the relevant therapeutic products. On the other hand, such regulations may retard product approval and impede R&D. Accordingly, national regulations for therapies based on genome-edited iPS cells are an important and, as the case may be, decisive factor for both researchers and industry regarding their decision where to locate their R&D activities. Therefore, regulatory frameworks impact significantly on the competitiveness of states and their economies. This is why a comparative analysis of laws and regulations of different countries matters. Such a comparative legal analysis provides an important insight into regulatory concepts which, in turn, may inspire adjustments of, or amendments to, domestic legal regimes. For this purpose, experts present country reports on France, Germany, Japan, South Korea, Switzerland, and the USA. The reports on France and Germany also refer to the parameters and implications arising from pertinent EU law. This contributed volume is aimed at researchers, but also at, e.g., legal scholars, lawmakers, regulators, and political decision makers.
650 0 $a Private international law. $3 1202562
650 0 $a Conflict of laws. $3 560163
650 0 $a International law. $3 557047
650 0 $a Comparative law. $3 560198
650 0 $a Law—Europe. $3 1254279
650 0 $a Medical genetics. $3 678508
650 1 4 $a Private International Law, International and Foreign Law, Comparative Law. $3 1365811
650 2 4 $a European Law. $3 883672
650 2 4 $a Medical Genetics. $3 1366169
700 1 $a Dederer, Hans-Georg. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1299090
700 1 $a Frenken, Gregor. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1393285
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030930226
776 0 8 $i Printed edition: $z 9783030930240
776 0 8 $i Printed edition: $z 9783030930257
856 4 0 $u https://doi.org/10.1007/978-3-030-93023-3
912 $a ZDB-2-LCR
912 $a ZDB-2-SXLC
950 $a Law and Criminology (SpringerNature-41177)
950 $a Law and Criminology (R0) (SpringerNature-43727)